MBX Biosciences (MBX) news
Recent news
Truist Securities raises target price to $88 from $70 for MBX Biosciences, Inc.
Truist Securities has revised its price target for MBX Biosciences, Inc. (MBX), raising it to $88 from the previous $70, while maintaining an Overweight rating on the stock. This adjustment follows an updated financial model based on the company’s second-quarter performance report. The increased…
AInvest Wire · Aug 10, 2026MBX Biosciences shares down 10% after the bell; announces executive leadership transition to support the company’s next phase of growth
MBX Biosciences has completed an immediate executive leadership transition, with Kent Hawryluk stepping down as president, CEO, and board member, and Steve Hoelter appointed as new chairman and CEO to support the company’s next phase of growth, with the changes taking effect immediately, as…
AInvest Wire · Jul 13, 2026MBX Biosciences names John Smither new CFO
MBX Biosciences, Inc. (NasdaqGS: MBX) has appointed John Smither as its Interim Chief Financial Officer, effective March 16, 2026, following the resignation of Richard Bartram, who will step down from his role as CFO on March 15, 2026. Bartram will continue to provide consulting services to the…
AInvest Wire · Jul 13, 2026MBX Biosciences - appoints Steve Hoelter as chairman and CEO
AInvest Wire · Jul 13, 2026MBX BioSciences announces executive leadership transition to support the company’s next phase of growth
AInvest Wire · Jul 13, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.